Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2019, Article ID 9046260, 9 pages
https://doi.org/10.1155/2019/9046260
Research Article

Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study

1Center for Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, China
2Department of Obstetrics and Gynaecology, Affiliated Hospital of Nantong University, Nantong 226001, China
3Department of Obstetrics and Gynaecology, Nantong Third People’s Hospital, Nantong University, Nantong 226006, China

Correspondence should be addressed to Guifang Gu; moc.qq@2678443781 and Gang Qin; nc.ude.utn@niqgynot

Received 5 December 2018; Revised 1 April 2019; Accepted 24 June 2019; Published 9 July 2019

Academic Editor: Michele Molinari

Copyright © 2019 Mengzhi Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. A total of 651 pregnant women aged 18-40 in Nantong Third People’s Hospital and Hospital affiliated to Nantong University with positive hepatitis B surface antigen (HBsAg) and HBV DNA were enrolled between January 2011 and December 2015. Patients with HBV DNA≥106 copies/mL (n=251) received LdT during late pregnancy according to the patients’ will, while 136 high viral patients with HBV DNA≥106 copies/mL who did not take LdT therapy and 268 low viral patients with HBV DNA<106 copies/mL served as the controls. Results. At 7 months and 1 year postpartum, the basal HBV DNA serum level of treated patients declined significantly (P<0.001), while no obvious decline was observed in the untreated high viraemic controls (P<0.05) and untreated low viraemic controls (P<0.05). Only 1 infant (0.4%) in LdT group was HBsAg positive at 7 months, while 14 (5.2%) were in the untreated low viraemic controls (P<0.001) and 15 (11.0%) were in untreated high viraemic controls (P<0.001). Conclusion. For pregnant women with HBV DNA≥106 copies/mL, the use of LdT during late pregnancy could effectively reduce the MTCT rate of HBV.